Phase

Zacks Small Cap Research – MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… – Go Health Pro

by
Zacks Small Cap Research – MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… – Go Health Pro

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of … Read more

Zacks Small Cap Research – DWTX: Interim Data for Phase 2b Trial in 4Q25… – Go Health Pro

by
Zacks Small Cap Research – DWTX: Interim Data for Phase 2b Trial in 4Q25… – Go Health Pro

By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced that the first patient was dosed in the Phase 2b HALT-CINP (Halneuron Treatment of Chemotherapy-Induced Neuropathic Pain) trial. This is a four-week study that … Read more

Zacks Small Cap Research – IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… – Go Health Pro

by
Zacks Small Cap Research – IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… – Go Health Pro

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On March 24, 2025, Imunon, Inc. (NASDAQ:IMNN) announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of … Read more

‘Trump’s war on science is the terminal phase of a long illness whose early signs were ignored’ – Go Health Pro

by
‘Trump’s war on science is the terminal phase of a long illness whose early signs were ignored’ – Go Health Pro

Since January 20, the news from America has been of an extravagant fervor, each morning presenting the avalanche of the previous day’s follies. The staggering spectacle offered day after day by the White House may be thrusting us a little more each day into a dystopia no one could have imagined arriving so quickly, but … Read more

Zacks Small Cap Research – CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… – Go Health Pro

by

By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. In August 2024, Cadrenal … Read more